Predicting liver deterioration and death in people with cirrhosis
Official title: Predictors of Decompensation, Acute-on-chronic Liver Failure and Mortality in Liver Cirrhosis - a Multicentre, Prospective, Observational Study From the SingHealth Chronic Liver Disease Registry (SoLiDaRity-DAM)
Run by Singapore General Hospital · NCT07438288 · Data updated 2026-11-12
This project will try to identify clinical signs and lab or imaging markers that predict worsening, acute-on-chronic liver failure (ACLF), or death in adults with cirrhosis treated at Singapore hospitals.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2200 (estimated) |
| Sponsor | Singapore General Hospital Academic / other |
| Locations | 3 sites (Singapore and 2 other locations) |
| Status | Recruiting |
| Started | August 12, 2022 |
| Main results expected | August 12, 2027 |
| Study ends | August 12, 2032 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT07438288 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and over with a clinical diagnosis of liver cirrhosis who receive care at the participating Singapore hospitals and are willing to give informed consent are ideal candidates.
✕Probably not a fit
People without clinical cirrhosis or those who do not consent will not be eligible, and participants should understand that because the study is observational they may not receive any direct treatment benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, non-interventional observational registry that will collect and analyze clinical data from hospital records of adults with cirrhosis seen at three Singapore hospitals. Investigators will track 1-, 3-, and 5-year risks of decompensation, ACLF, and death and record specific liver-related complications and candidate biomarkers. The study will test and externally validate existing predictive scores (ALBI, CHESS-ALARM, LSPS, PREDICT) and examine how different disease causes influence outcomes. It will also act as a core hub for future ancillary studies on diagnosis, prognosis, and pathogenesis of acute decompensation and ACLF.
Why it matters
Potential benefit: If successful, clinicians could identify high-risk patients earlier and target interventions to prevent or delay complications like decompensation, ACLF, and death.
How similar studies have gone: Previous research using clinical predictors and scoring systems has shown promise and some models (for example ALBI and PREDICT) have been externally validated, though prospective hub registries for ACLF prediction are relatively limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with clinical diagnosis of liver cirrhosis 2. Age 18 years and above (parental consent required if below 21 years) 3. Willing and able to provide informed consent Exclusion Criteria: * No clinical evidence of liver cirrhosis * Not willing to provide informed consent
Where it's running
-
Changi General Hospital
Singapore, Singapore Recruiting -
Sengkang General Hospital
Singapore, Singapore Recruiting -
Singapore General Hospital
Singapore, Singapore Recruiting
Study contacts
- Study coordinator: Jason Pik Eu Chang, MBBS, MRCP
- Email: jason.chang@singhealth.com.sg
- Phone: +65 6321 4684
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Microplastics in the liver of people with cirrhosis and portal hypertension
This study tests whether microplastics and nanoparticles accumulate in the livers of adults with cirrhosis and portal hypertension who are undergoing surgery or transplant, to understand where they go and what form they take.
-
Abbreviated non-contrast MRI versus ultrasound for finding liver cancer in people with cirrhosis
We will test whether shorter MRI scans without contrast find liver cancer more reliably than routine ultrasound in adults with cirrhosis or otherwise at high risk.
-
Magnetic Resonance Cholangiopancreatography to help living liver donors and their recipients
This study tests whether preoperative MRCP imaging can help select living liver donors and reduce biliary complications in recipients.
-
Genetic factors in graft fatty liver after living-donor liver transplant
This study will see if donor and recipient genetic variants, especially PNPLA3 and MBOAT7, are linked to fat buildup in the transplanted liver among adults who had living-donor liver transplants for MAFLD-related cirrhosis.
-
How liver transplant affects sexual life and function
This project will try to see if sexual function improves after liver transplant in married men with decompensated chronic liver disease and in men who already have a stable liver transplant.
-
Gathering data on hepatomiR for liver disease outcomes
This study is trying to see how a new test for liver disease can help doctors understand and predict serious problems in patients with chronic liver issues.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.